343 related articles for article (PubMed ID: 31753111)
41. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
42. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
[TBL] [Abstract][Full Text] [Related]
43. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
44. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
Haugh A; Daud AI
Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
[TBL] [Abstract][Full Text] [Related]
46. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
47. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
Akabane H; Sullivan RJ
Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
[TBL] [Abstract][Full Text] [Related]
48. BRAF mutation-positive folliculotropic metastatic melanoma.
Brick KE; Halling KC; Khan YK; Peters MS
Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
[TBL] [Abstract][Full Text] [Related]
49. BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Curr Cancer Drug Targets; 2014; 14(2):128-43. PubMed ID: 24446739
[TBL] [Abstract][Full Text] [Related]
50. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
[TBL] [Abstract][Full Text] [Related]
51. What, if Any, Role Is There for BRAF-Targeted Therapy in
Sullivan RJ
J Clin Oncol; 2022 Dec; 40(36):4161-4165. PubMed ID: 35862870
[No Abstract] [Full Text] [Related]
52. Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.
Rogiers A; Vander Borght S; Tuand K; Wolter P; Stas M; Boecxstaens V; Garmyn M; van den Oord JJ; Vandenberghe P; Bechter O
Melanoma Res; 2017 Oct; 27(5):507-510. PubMed ID: 28800030
[TBL] [Abstract][Full Text] [Related]
53. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
Hadfield MJ; Sullivan RJ
Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
[TBL] [Abstract][Full Text] [Related]
54. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
55. [Melanoma: from molecular studies to the treatment breakthrough].
Imianitov EN
Arkh Patol; 2013; 75(5):63-72. PubMed ID: 24341237
[TBL] [Abstract][Full Text] [Related]
56. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
57. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
58. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
59. Sequencing of Targeted Treatment and Immunotherapy in Advanced
Devlin O; Oladipo O
J Clin Oncol; 2023 Apr; 41(12):2295-2296. PubMed ID: 36791370
[No Abstract] [Full Text] [Related]
60. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
Eur J Cancer; 2017 Mar; 73():85-92. PubMed ID: 28169047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
